Betulonic acid
Based on 5 publication(s) in Google Scholar
Betulonic acid (Betunolic acid), a naturally occurring triterpene, is found in many plants. Betulonic acid has anti-tumor, anti-inflammatory, antiparasitic and anti-viral (HSV-1) activities.
For research use only. We do not sell to patients.
- Purity: 99.52%
- CAS No.: 4481-62-3
- Formula: C30H46O3
- Molecular Weight:454.68
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
Publications Citing Use of MedChemExpress (MCE) Betulonic acid
MoreAll Parasite Isoforms
More
Biological Activity
|
Plasmodium |
HSV-1 |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| 518A2 | EC50 |
29 μM
Compound: 4
|
Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay
Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay
|
[PMID: 26547057] |
| 518A2 | IC50 |
10.42 μM
Compound: 2
|
Cytotoxicity against human 518A2 cells after 96 hrs by SRB colorimetric assay
Cytotoxicity against human 518A2 cells after 96 hrs by SRB colorimetric assay
|
[PMID: 20472329] |
| 518A2 | IC50 |
12.93 μM
Compound: 2
|
Cytotoxicity against human 518A2 cells assessed as cell viability after 96 hrs by SRB assay
Cytotoxicity against human 518A2 cells assessed as cell viability after 96 hrs by SRB assay
|
[PMID: 23973824] |
| 8505C | IC50 |
14 μM
Compound: 2
|
Cytotoxicity against human 8505C cells assessed as cell viability after 96 hrs by SRB assay
Cytotoxicity against human 8505C cells assessed as cell viability after 96 hrs by SRB assay
|
[PMID: 23973824] |
| A253 cell line | IC50 |
10.05 μM
Compound: 2
|
Cytotoxicity against human A253 cells after 96 hrs by SRB colorimetric assay
Cytotoxicity against human A253 cells after 96 hrs by SRB colorimetric assay
|
[PMID: 20472329] |
| A2780 | EC50 |
20.4 μM
Compound: 4
|
Cytotoxicity against human A2780 cells after 96 hrs by SRB assay
Cytotoxicity against human A2780 cells after 96 hrs by SRB assay
|
[PMID: 26547057] |
| A2780 | EC50 |
4.7 μM
Compound: 2
|
Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
|
[PMID: 32956968] |
| A2780 | IC50 |
2.98 μM
Compound: 2
|
Cytotoxicity against human A2780 cells after 96 hrs by SRB colorimetric assay
Cytotoxicity against human A2780 cells after 96 hrs by SRB colorimetric assay
|
[PMID: 20472329] |
| A2780 | IC50 |
5.97 μM
Compound: 2
|
Cytotoxicity against human A2780 cells assessed as cell viability after 96 hrs by SRB assay
Cytotoxicity against human A2780 cells assessed as cell viability after 96 hrs by SRB assay
|
[PMID: 23973824] |
| A-375 | EC50 |
14.3 μM
Compound: 2
|
Cytotoxicity against human A-375 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
Cytotoxicity against human A-375 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
|
[PMID: 32956968] |
| A-375 | IC50 |
28.9 μM
Compound: 1, BetA, Betulonic acid
|
Cytotoxicity against human A375 cells after 72 hrs by MTT assay
Cytotoxicity against human A375 cells after 72 hrs by MTT assay
|
[PMID: 25874331] |
| A-431 | IC50 |
3.26 μM
Compound: 2
|
Cytotoxicity against human A431 cells after 96 hrs by SRB colorimetric assay
Cytotoxicity against human A431 cells after 96 hrs by SRB colorimetric assay
|
[PMID: 20472329] |
| A549 | EC50 |
25.9 μM
Compound: 4
|
Cytotoxicity against human A549 cells after 96 hrs by SRB assay
Cytotoxicity against human A549 cells after 96 hrs by SRB assay
|
[PMID: 26547057] |
| A549 | ED50 |
>10 μg/mL
Compound: 13
|
Cytotoxic activity against human A549 cell line was measured after 72 hr using MTT assay
Cytotoxic activity against human A549 cell line was measured after 72 hr using MTT assay
|
[PMID: 15225732] |
| A549 | IC50 |
10.09 μM
Compound: 2
|
Cytotoxicity against human A549 cells after 96 hrs by SRB colorimetric assay
Cytotoxicity against human A549 cells after 96 hrs by SRB colorimetric assay
|
[PMID: 20472329] |
| A549 | IC50 |
10.42 μM
Compound: 2
|
Cytotoxicity against human A549 cells assessed as cell viability after 96 hrs by SRB assay
Cytotoxicity against human A549 cells assessed as cell viability after 96 hrs by SRB assay
|
[PMID: 23973824] |
| A549 | IC50 |
15 μM
Compound: 1b
|
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
|
[PMID: 17371067] |
| A549 | IC50 |
15 μM
Compound: 7, betulonic acid
|
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
|
[PMID: 15270560] |
| A549 | IC50 |
40 μM
Compound: 5a
|
Cytotoxicity against human A549 cells incubated for 72 hrs by MTS assay
Cytotoxicity against human A549 cells incubated for 72 hrs by MTS assay
|
[PMID: 31677446] |
| A549 | IC50 |
40 μM
Compound: 1a
|
Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay
|
[PMID: 36174412] |
| A549 | IC50 |
5.7 μM
Compound: 7
|
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by SRB assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by SRB assay
|
[PMID: 28500966] |
| A549 | IC50 |
8.93 μg/mL
Compound: Betunolic acid
|
Cytotoxicity against human A549 cells by MTT assay
Cytotoxicity against human A549 cells by MTT assay
|
[PMID: 21106454] |
| Bcap37 | IC50 |
25.7 μM
Compound: 1, BetA, Betulonic acid
|
Cytotoxicity against human Bcap37 cells after 72 hrs by MTT assay
Cytotoxicity against human Bcap37 cells after 72 hrs by MTT assay
|
[PMID: 25874331] |
| BJ | IC50 |
39 μM
Compound: 1a
|
Cytotoxicity against human BJ cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay
Cytotoxicity against human BJ cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay
|
[PMID: 36174412] |
| BJ | IC50 |
39.5 μM
Compound: 5a
|
Cytotoxicity against human BJ cells incubated for 72 hrs by MTS assay
Cytotoxicity against human BJ cells incubated for 72 hrs by MTS assay
|
[PMID: 31677446] |
| BRISTOL8 | ED50 |
2.6 μg/mL
Compound: 13
|
Cytotoxic activity against human BRISTOL8 cell line was measured after 72 hr using MTT assay
Cytotoxic activity against human BRISTOL8 cell line was measured after 72 hr using MTT assay
|
[PMID: 15225732] |
| BV-2 | IC50 |
>100 μM
Compound: 28
|
Anti-neuroinflammatory activity against mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay
Anti-neuroinflammatory activity against mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay
|
[PMID: 25466192] |
| BV-2 | IC50 |
60.7 μM
Compound: 1
|
Anti-neuroinflammatory activity in mouse BV-2 cells assessed as inhibition of LPS-induced NO production incubated for 48 hrs by Griess reagent based assay
Anti-neuroinflammatory activity in mouse BV-2 cells assessed as inhibition of LPS-induced NO production incubated for 48 hrs by Griess reagent based assay
|
[PMID: 34546050] |
| Ca9-22 | IC50 |
14.47 μg/mL
Compound: Betunolic acid
|
Cytotoxicity against human Ca9-22 cells by MTT assay
Cytotoxicity against human Ca9-22 cells by MTT assay
|
[PMID: 21106454] |
| CCRF-CEM | ED50 |
4.4 μg/mL
Compound: 13
|
Cytotoxic activity against human CEM.CM3 cell line was measured after 72 hr using MTT assay
Cytotoxic activity against human CEM.CM3 cell line was measured after 72 hr using MTT assay
|
[PMID: 15225732] |
| CCRF-CEM | IC50 |
14 μM
Compound: 2a
|
Cytotoxicity against human CCRF-CEM cells after 72 hrs by MTS assay
Cytotoxicity against human CCRF-CEM cells after 72 hrs by MTS assay
|
[PMID: 27236068] |
| CCRF-CEM | IC50 |
17 μM
Compound: 7, betulonic acid
|
Cytotoxicity against human CEM cells after 72 hrs by MTT assay
Cytotoxicity against human CEM cells after 72 hrs by MTT assay
|
[PMID: 15270560] |
| CCRF-CEM | IC50 |
20 μM
Compound: 1b
|
Cytotoxicity against human CEM cells after 72 hrs by MTT assay
Cytotoxicity against human CEM cells after 72 hrs by MTT assay
|
[PMID: 17371067] |
| CCRF-CEM | IC50 |
20 μM
Compound: 3
|
Cytotoxicity against human CCRF-CEM cells after 72 hrs by MTT assay
Cytotoxicity against human CCRF-CEM cells after 72 hrs by MTT assay
|
[PMID: 22551630] |
| CCRF-CEM | IC50 |
8.4 μM
Compound: 5a
|
Cytotoxicity against human CCRF-CEM cells incubated for 72 hrs by MTS assay
Cytotoxicity against human CCRF-CEM cells incubated for 72 hrs by MTS assay
|
[PMID: 31677446] |
| CCRF-CEM | IC50 |
8.4 μM
Compound: 1a
|
Cytotoxicity against human CCRF-CEM cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay
Cytotoxicity against human CCRF-CEM cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay
|
[PMID: 36174412] |
| CEM-DNR | IC50 |
11 μM
Compound: 1a
|
Cytotoxicity against human CEM-DNR cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay
Cytotoxicity against human CEM-DNR cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay
|
[PMID: 36174412] |
| CHO | EC50 |
4.71 μM
Compound: 7
|
Agonist activity at TGR5 expressed in CHO cells by CRE-driven luciferase reporter gene assay
Agonist activity at TGR5 expressed in CHO cells by CRE-driven luciferase reporter gene assay
|
[PMID: 19911773] |
| COLO 205 | IC50 |
36.8 μM
Compound: 17
|
Cytotoxicity against human COLON205 cells after 48 hrs by MTT assay
Cytotoxicity against human COLON205 cells after 48 hrs by MTT assay
|
[PMID: 17346076] |
| COS-1 | EC50 |
0 μM
Compound: 7
|
Agonist activity at human FXR expressed in COS1 cells by luciferase reporter gene assay
Agonist activity at human FXR expressed in COS1 cells by luciferase reporter gene assay
|
[PMID: 19911773] |
| DU-145 | CC50 |
139 μM
Compound: 9
|
Cytotoxic activity in human DU145 cells by sulforhodamine B assay
Cytotoxic activity in human DU145 cells by sulforhodamine B assay
|
[PMID: 29120172] |
| DU-145 | ED50 |
3.1 μg/mL
Compound: 13
|
Cytotoxic activity against human DU145 cell line was measured after 72 hr using MTT assay
Cytotoxic activity against human DU145 cell line was measured after 72 hr using MTT assay
|
[PMID: 15225732] |
| DU-145 | IC50 |
>500 μM
Compound: 9
|
Antiproliferative activity in human DU145 cells by sulforhodamine B assay
Antiproliferative activity in human DU145 cells by sulforhodamine B assay
|
[PMID: 29120172] |
| DU-145 | IC50 |
36 μM
Compound: 7, betulonic acid
|
Cytotoxicity against human DU145 cells after 72 hrs by MTT assay
Cytotoxicity against human DU145 cells after 72 hrs by MTT assay
|
[PMID: 15270560] |
| ECV-304 | IC50 |
<4 μg/mL
Compound: 12
|
Cytotoxic activity against ECV304 (human endothelial) cell line.
Cytotoxic activity against ECV304 (human endothelial) cell line.
|
[PMID: 15149668] |
| ECV-304 | IC50 |
0.28 μg/mL
Compound: 2
|
Half-maximal cytotoxic concentration of compound against endothelial cell line ECV304
Half-maximal cytotoxic concentration of compound against endothelial cell line ECV304
|
[PMID: 15081004] |
| FaDu | EC50 |
17.4 μM
Compound: 2
|
Cytotoxicity against human FaDu cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
Cytotoxicity against human FaDu cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
|
[PMID: 32956968] |
| Fibroblast | CC50 |
>100 μM
Compound: 2
|
Cytotoxicity against mock-infected human embryonic lung fibroblast cells incubated for 5 days by MTS assay
Cytotoxicity against mock-infected human embryonic lung fibroblast cells incubated for 5 days by MTS assay
|
[PMID: 33877845] |
| H9 | EC50 |
0.22 μg/mL
Compound: 4
|
Antiviral activity against HIV1 3B infected in human H9 cells assessed as inhibition of viral p24 antigen levels after 4 days by ELISA
Antiviral activity against HIV1 3B infected in human H9 cells assessed as inhibition of viral p24 antigen levels after 4 days by ELISA
|
[PMID: 11678650] |
| H9 | IC50 |
1.8 μg/mL
Compound: 4
|
Cytotoxicity against human H9 cells
Cytotoxicity against human H9 cells
|
[PMID: 11678650] |
| HCT-116 | IC50 |
>10 μM
Compound: 7
|
Cytotoxicity against human HCT116 cells assessed as reduction in cell viability after 48 hrs by SRB assay
Cytotoxicity against human HCT116 cells assessed as reduction in cell viability after 48 hrs by SRB assay
|
[PMID: 28500966] |
| HCT-116 | IC50 |
2.61 μM
Compound: 6
|
Antiproliferative activity against human HCT116 cells after 3 days by XTT assay
Antiproliferative activity against human HCT116 cells after 3 days by XTT assay
|
[PMID: 19691293] |
| HCT-116 | IC50 |
38 μM
Compound: 1a
|
Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay
Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay
|
[PMID: 36174412] |
| HCT-116 | IC50 |
38.1 μM
Compound: 5a
|
Cytotoxicity against human HCT116 cells incubated for 72 hrs by MTS assay
Cytotoxicity against human HCT116 cells incubated for 72 hrs by MTS assay
|
[PMID: 31677446] |
| HCT-116 | IC50 |
49.4 μM
Compound: 5a
|
Cytotoxicity against p53 knockout human HCT116 cells incubated for 72 hrs by MTS assay
Cytotoxicity against p53 knockout human HCT116 cells incubated for 72 hrs by MTS assay
|
[PMID: 31677446] |
| HEK293 | CC50 |
>500 μM
Compound: 9
|
Cytotoxic activity in HEK293 cells by sulforhodamine B assay
Cytotoxic activity in HEK293 cells by sulforhodamine B assay
|
[PMID: 29120172] |
| HEK293 | IC50 |
>500 μM
Compound: 9
|
Antiproliferative activity in HEK293 cells by sulforhodamine B assay
Antiproliferative activity in HEK293 cells by sulforhodamine B assay
|
[PMID: 29120172] |
| HeLa | CC50 |
>500 μM
Compound: 9
|
Cytotoxic activity in human HeLa cells by sulforhodamine B assay
Cytotoxic activity in human HeLa cells by sulforhodamine B assay
|
[PMID: 29120172] |
| HeLa | IC50 |
>500 μM
Compound: 9
|
Antiproliferative activity in human HeLa cells by sulforhodamine B assay
Antiproliferative activity in human HeLa cells by sulforhodamine B assay
|
[PMID: 29120172] |
| Hep 3B2 | IC50 |
13.81 μg/mL
Compound: Betunolic acid
|
Cytotoxicity against human Hep3B cells by MTT assay
Cytotoxicity against human Hep3B cells by MTT assay
|
[PMID: 21106454] |
| HEp-2 | CC50 |
>500 μM
Compound: 9
|
Cytotoxic activity in human Hep2 cells by sulforhodamine B assay
Cytotoxic activity in human Hep2 cells by sulforhodamine B assay
|
[PMID: 29120172] |
| HEp-2 | IC50 |
>500 μM
Compound: 9
|
Antiproliferative activity in human Hep2 cells by sulforhodamine B assay
Antiproliferative activity in human Hep2 cells by sulforhodamine B assay
|
[PMID: 29120172] |
| HepG2 | CC50 |
150.5 μM
Compound: 4b
|
Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
|
[PMID: 29326018] |
| HepG2 | IC50 |
4.32 μg/mL
Compound: Betunolic acid
|
Cytotoxicity against human HepG2 cells by MTT assay
Cytotoxicity against human HepG2 cells by MTT assay
|
[PMID: 21106454] |
| HT-29 | EC50 |
18.5 μM
Compound: 2
|
Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
|
[PMID: 32956968] |
| HT-29 | IC50 |
10.02 μM
Compound: 2
|
Cytotoxicity against human HT-29 cells after 96 hrs by SRB colorimetric assay
Cytotoxicity against human HT-29 cells after 96 hrs by SRB colorimetric assay
|
[PMID: 20472329] |
| HT-29 | IC50 |
17 μM
Compound: 1b
|
Cytotoxicity against human HT29 cells after 72 hrs by MTT assay
Cytotoxicity against human HT29 cells after 72 hrs by MTT assay
|
[PMID: 17371067] |
| HT-29 | IC50 |
17 μM
Compound: 7, betulonic acid
|
Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay
Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay
|
[PMID: 15270560] |
| Jurkat | ED50 |
0.4 μg/mL
Compound: 13
|
Cytotoxic activity against human JurkatE6.1 cell line was measured after 72 h using MTT assay
Cytotoxic activity against human JurkatE6.1 cell line was measured after 72 h using MTT assay
|
[PMID: 15225732] |
| K562 | IC50 |
13.6 μM
Compound: 5a
|
Cytotoxicity against human K562 cells incubated for 72 hrs by MTS assay
Cytotoxicity against human K562 cells incubated for 72 hrs by MTS assay
|
[PMID: 31677446] |
| K562 | IC50 |
14 μM
Compound: 1a
|
Cytotoxicity against human K562 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay
Cytotoxicity against human K562 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay
|
[PMID: 36174412] |
| K562 | IC50 |
16.1 μM
Compound: 17
|
Cytotoxicity against human K562 cells after 48 hrs by MTT assay
Cytotoxicity against human K562 cells after 48 hrs by MTT assay
|
[PMID: 17346076] |
| K562 | IC50 |
17 μM
Compound: 7, betulonic acid
|
Cytotoxicity against paclitaxel-resistant human K562 cells after 72 hrs by MTT assay
Cytotoxicity against paclitaxel-resistant human K562 cells after 72 hrs by MTT assay
|
[PMID: 15270560] |
| K562 | IC50 |
6 μM
Compound: 1b
|
Cytotoxicity against human K562 cells after 72 hrs by MTT assay
Cytotoxicity against human K562 cells after 72 hrs by MTT assay
|
[PMID: 17371067] |
| K562 | IC50 |
6 μM
Compound: 7, betulonic acid
|
Cytotoxicity against human K562 cells after 72 hrs by MTT assay
Cytotoxicity against human K562 cells after 72 hrs by MTT assay
|
[PMID: 15270560] |
| K562/Adr | IC50 |
48.4 μM
Compound: 17
|
Cytotoxicity against human doxorubicin-resistant K562/Adr cells in presence of 1 uM doxorubicin after 48 hrs by MTT assay
Cytotoxicity against human doxorubicin-resistant K562/Adr cells in presence of 1 uM doxorubicin after 48 hrs by MTT assay
|
[PMID: 17346076] |
| K562/Adr | IC50 |
73.5 μM
Compound: 17
|
Cytotoxicity against human doxorubicin-resistant K562/Adr cells after 48 hrs by MTT assay
Cytotoxicity against human doxorubicin-resistant K562/Adr cells after 48 hrs by MTT assay
|
[PMID: 17346076] |
| KB | CC50 |
>500 μM
Compound: 9
|
Cytotoxic activity in human KB cells by sulforhodamine B assay
Cytotoxic activity in human KB cells by sulforhodamine B assay
|
[PMID: 29120172] |
| KB | ED50 |
2.5 μg/mL
Compound: 3
|
Cytotoxicity against human epidermoid carcinoma of the mouth (KB) cell line.
Cytotoxicity against human epidermoid carcinoma of the mouth (KB) cell line.
|
[PMID: 9873420] |
| KB | IC50 |
>500 μM
Compound: 9
|
Antiproliferative activity in human KB cells by sulforhodamine B assay
Antiproliferative activity in human KB cells by sulforhodamine B assay
|
[PMID: 29120172] |
| KB | IC50 |
3.8 μM
Compound: 17
|
Cytotoxicity against human KB cells after 48 hrs by MTT assay
Cytotoxicity against human KB cells after 48 hrs by MTT assay
|
[PMID: 17346076] |
| L132 | ED50 |
>10 μg/mL
Compound: 13
|
Cytotoxic activity against human L132 cell line was measured after 72 hr using MTT assay
Cytotoxic activity against human L132 cell line was measured after 72 hr using MTT assay
|
[PMID: 15225732] |
| MCF7 | CC50 |
>500 μM
Compound: 9
|
Cytotoxic activity in human MCF7 cells by sulforhodamine B assay
Cytotoxic activity in human MCF7 cells by sulforhodamine B assay
|
[PMID: 29120172] |
| MCF7 | EC50 |
12 μM
Compound: 2
|
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
|
[PMID: 32956968] |
| MCF7 | EC50 |
25.9 μM
Compound: 4
|
Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay
Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay
|
[PMID: 26547057] |
| MCF7 | IC50 |
>10 μM
Compound: 7
|
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by SRB assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by SRB assay
|
[PMID: 28500966] |
| MCF7 | IC50 |
>500 μM
Compound: 9
|
Antiproliferative activity in human MCF7 cells by sulforhodamine B assay
Antiproliferative activity in human MCF7 cells by sulforhodamine B assay
|
[PMID: 29120172] |
| MCF7 | IC50 |
10.37 μM
Compound: 2
|
Cytotoxicity against human MCF7 cells after 96 hrs by SRB colorimetric assay
Cytotoxicity against human MCF7 cells after 96 hrs by SRB colorimetric assay
|
[PMID: 20472329] |
| MCF7 | IC50 |
10.42 μM
Compound: 2
|
Cytotoxicity against human MCF7 cells assessed as cell viability after 96 hrs by SRB assay
Cytotoxicity against human MCF7 cells assessed as cell viability after 96 hrs by SRB assay
|
[PMID: 23973824] |
| MCF7 | IC50 |
18.2 μM
Compound: 1, BetA, Betulonic acid
|
Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
|
[PMID: 25874331] |
| MCF7 | IC50 |
19.32 μg/mL
Compound: Betunolic acid
|
Cytotoxicity against human MCF7 cells by MTT assay
Cytotoxicity against human MCF7 cells by MTT assay
|
[PMID: 21106454] |
| MCF7 | IC50 |
29 μM
Compound: 7, betulonic acid
|
Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
|
[PMID: 15270560] |
| MCF7 | IC50 |
49 μM
Compound: 17
|
Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
|
[PMID: 17346076] |
| MDA-MB-231 | CC50 |
60.9 μM
Compound: 9
|
Cytotoxic activity in human MDA-MB-231 cells by sulforhodamine B assay
Cytotoxic activity in human MDA-MB-231 cells by sulforhodamine B assay
|
[PMID: 29120172] |
| MDA-MB-231 | IC50 |
>20 μg/mL
Compound: Betunolic acid
|
Cytotoxicity against human MDA-MB-231 cells by MTT assay
Cytotoxicity against human MDA-MB-231 cells by MTT assay
|
[PMID: 21106454] |
| MDA-MB-231 | IC50 |
>500 μM
Compound: 9
|
Antiproliferative activity in human MDA-MB-231 cells by sulforhodamine B assay
Antiproliferative activity in human MDA-MB-231 cells by sulforhodamine B assay
|
[PMID: 29120172] |
| MDA-MB-231 | IC50 |
9.77 μM
Compound: 6
|
Antiproliferative activity against human MDA-MB-231 cells after 3 days by MTT assay
Antiproliferative activity against human MDA-MB-231 cells after 3 days by MTT assay
|
[PMID: 19691293] |
| MGC-803 | IC50 |
17.7 μM
Compound: 1, BetA, Betulonic acid
|
Cytotoxicity against human MGC803 cells after 72 hrs by MTT assay
Cytotoxicity against human MGC803 cells after 72 hrs by MTT assay
|
[PMID: 25874331] |
| MIA PaCa-2 | IC50 |
>10 μM
Compound: 7
|
Cytotoxicity against human MIAPaCa2 cells assessed as reduction in cell viability after 48 hrs by SRB assay
Cytotoxicity against human MIAPaCa2 cells assessed as reduction in cell viability after 48 hrs by SRB assay
|
[PMID: 28500966] |
| MOLT-4 | ED50 |
1.2 μg/mL
Compound: 13
|
Cytotoxic activity against human MOLT-4 cell line was measured after 72 hr using MTT assay
Cytotoxic activity against human MOLT-4 cell line was measured after 72 hr using MTT assay
|
[PMID: 15225732] |
| MRC5 | IC50 |
29.5 μM
Compound: 5a
|
Cytotoxicity against human MRC5 cells incubated for 72 hrs by MTS assay
Cytotoxicity against human MRC5 cells incubated for 72 hrs by MTS assay
|
[PMID: 31677446] |
| MRC5 | IC50 |
30 μM
Compound: 1a
|
Cytotoxicity against human MRC5 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay
Cytotoxicity against human MRC5 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay
|
[PMID: 36174412] |
| Neutrophil | IC50 |
127.64 μg/mL
Compound: Betunolic acid
|
Antiinflammatory activity in human Neutrophil assessed as inhibition of elastase release at 10 ug/ml
Antiinflammatory activity in human Neutrophil assessed as inhibition of elastase release at 10 ug/ml
|
[PMID: 21106454] |
| Neutrophil | IC50 |
16.77 μg/mL
Compound: Betunolic acid
|
Antiinflammatory activity in human Neutrophil assessed as inhibition of superoxide anion release at 10 ug/ml
Antiinflammatory activity in human Neutrophil assessed as inhibition of superoxide anion release at 10 ug/ml
|
[PMID: 21106454] |
| NIH3T3 | EC50 |
13.1 μM
Compound: 4
|
Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay
Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay
|
[PMID: 26547057] |
| NIH3T3 | EC50 |
19.4 μM
Compound: 2
|
Cytotoxicity against mouse NIH3T3 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
Cytotoxicity against mouse NIH3T3 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
|
[PMID: 32956968] |
| PA-1 | ED50 |
1.2 μg/mL
Compound: 13
|
Cytotoxic activity against human PA-1 cell line was measured after 72 hr using MTT assay
Cytotoxic activity against human PA-1 cell line was measured after 72 hr using MTT assay
|
[PMID: 15225732] |
| PC-3 | IC50 |
>10 μM
Compound: 7
|
Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 48 hrs by SRB assay
Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 48 hrs by SRB assay
|
[PMID: 28500966] |
| PC-3 | IC50 |
13.9 μM
Compound: 1, BetA, Betulonic acid
|
Cytotoxicity against human PC3 cells after 72 hrs by MTT assay
Cytotoxicity against human PC3 cells after 72 hrs by MTT assay
|
[PMID: 25874331] |
| PC-3 | IC50 |
15 μM
Compound: 1b
|
Cytotoxicity against human PC3 cells after 72 hrs by MTT assay
Cytotoxicity against human PC3 cells after 72 hrs by MTT assay
|
[PMID: 17371067] |
| PC-3 | IC50 |
15 μM
Compound: 7, betulonic acid
|
Cytotoxicity against human PC3 cells after 72 hrs by MTT assay
Cytotoxicity against human PC3 cells after 72 hrs by MTT assay
|
[PMID: 15270560] |
| Platelet | IC50 |
>50 μg/mL
Compound: Betunolic acid
|
Antiaggregatory activity in human platelets assessed as inhibition of thrombin-induced platelet aggregation by aggregometry
Antiaggregatory activity in human platelets assessed as inhibition of thrombin-induced platelet aggregation by aggregometry
|
[PMID: 21106454] |
| Platelet | IC50 |
44.71 μg/mL
Compound: Betunolic acid
|
Antiaggregatory activity in human platelets assessed as inhibition of collagen-induced platelet aggregation by aggregometry
Antiaggregatory activity in human platelets assessed as inhibition of collagen-induced platelet aggregation by aggregometry
|
[PMID: 21106454] |
| SiHa | CC50 |
116.8 μM
Compound: 9
|
Cytotoxic activity in human SiHa cells by sulforhodamine B assay
Cytotoxic activity in human SiHa cells by sulforhodamine B assay
|
[PMID: 29120172] |
| SiHa | IC50 |
>500 μM
Compound: 9
|
Antiproliferative activity in human SiHa cells by sulforhodamine B assay
Antiproliferative activity in human SiHa cells by sulforhodamine B assay
|
[PMID: 29120172] |
| SK-MEL-2 | ED50 |
0.9 μg/mL
Compound: 3
|
Cytotoxicity against cultured human melanoma (MEL-2) cell line.
Cytotoxicity against cultured human melanoma (MEL-2) cell line.
|
[PMID: 9873420] |
| SK-MEL-2 | IC50 |
26 μM
Compound: 1b
|
Cytotoxicity against human SK-MEL-2 cells after 72 hrs by MTT assay
Cytotoxicity against human SK-MEL-2 cells after 72 hrs by MTT assay
|
[PMID: 17371067] |
| SK-MEL-2 | IC50 |
26 μM
Compound: 7, betulonic acid
|
Cytotoxicity against human SK-MEL-2 cells after 72 hrs by MTT assay
Cytotoxicity against human SK-MEL-2 cells after 72 hrs by MTT assay
|
[PMID: 15270560] |
| SW-1736 | IC50 |
3.05 μM
Compound: 2
|
Cytotoxicity against human SW1736 cells after 96 hrs by SRB colorimetric assay
Cytotoxicity against human SW1736 cells after 96 hrs by SRB colorimetric assay
|
[PMID: 20472329] |
| SW948 | IC50 |
19.17 μM
Compound: 6
|
Antiproliferative activity against human SW948 cells after 3 days by XTT assay
Antiproliferative activity against human SW948 cells after 3 days by XTT assay
|
[PMID: 19691293] |
| U2OS | IC50 |
38 μM
Compound: 5a
|
Cytotoxicity against human U2OS cells incubated for 72 hrs by MTS assay
Cytotoxicity against human U2OS cells incubated for 72 hrs by MTS assay
|
[PMID: 31677446] |
| U2OS | IC50 |
38 μM
Compound: 1a
|
Cytotoxicity against human U2OS cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay
Cytotoxicity against human U2OS cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay
|
[PMID: 36174412] |
| U-87MG ATCC | IC50 |
159 μM
Compound: 1b
|
Cytotoxicity against human U87-Mg cells after 72 hrs by MTT assay
Cytotoxicity against human U87-Mg cells after 72 hrs by MTT assay
|
[PMID: 17371067] |
| U-937 | ED50 |
2.8 μg/mL
Compound: 13
|
Cytotoxic activity against human U937 cell line was measured after 72 hr using MTT assay
Cytotoxic activity against human U937 cell line was measured after 72 hr using MTT assay
|
[PMID: 15225732] |
| Vero | CC50 |
>400 μM
Compound: 4b
|
Cytotoxicity against African green monkey Vero cells after 72 hrs by MTT assay
Cytotoxicity against African green monkey Vero cells after 72 hrs by MTT assay
|
[PMID: 29326018] |
| Vero | CC50 |
>500 μM
Compound: 9
|
Cytotoxic activity in African green monkey Vero cells by sulforhodamine B assay
Cytotoxic activity in African green monkey Vero cells by sulforhodamine B assay
|
[PMID: 29120172] |
| Vero | CC50 |
112 μM
Compound: 14
|
Cytotoxicity against Vero E6 cells by MTT assay
Cytotoxicity against Vero E6 cells by MTT assay
|
[PMID: 17663539] |
| Vero | CC50 |
35.6 μM
Compound: Betulonic acid
|
Cytotoxicity against African green monkey Vero cells assessed as cell viability after 2 days by trypan blue exclusion assay
Cytotoxicity against African green monkey Vero cells assessed as cell viability after 2 days by trypan blue exclusion assay
|
[PMID: 26112446] |
| Vero | EC50 |
0.63 μM
Compound: 14
|
Antiviral activity against SARS coronavirus in Vero E6 cells assessed as inhibition of viral replication by ELISA
Antiviral activity against SARS coronavirus in Vero E6 cells assessed as inhibition of viral replication by ELISA
|
[PMID: 17663539] |
| Vero | IC50 |
>500 μM
Compound: 9
|
Antiproliferative activity in African green monkey Vero cells by sulforhodamine B assay
Antiproliferative activity in African green monkey Vero cells by sulforhodamine B assay
|
[PMID: 29120172] |
Betulonic acid (72 h) inhibits the growth of various types of human tumor cell lines, including MGC-803, PC3, Bcap-37, A375, MCF-7 tumor cell lines, with IC50s of 17.7, 13.9, 25.7, 28.9, 18.2 μM, respectively[2].
Betulonic acid has antiplasmodial activity, with IC50 of 10 μM[3].
Betulonic acid inhibits HSV-1, ECHO6 and influenza FPV viruses, with EC50s of 0.9, 73.32, and 5.7 μM, respectively[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 4481-62-3
-
Appearance Solid
-
Molecular Weight 454.68
-
Formula C30H46O3
-
Color White to off-white
-
SMILES
CC1(C)C(CC[C@]2(C)[C@@]3([H])CC[C@]4([H])[C@@]5([H])[C@H](C(C)=C)CC[C@@](C(O)=O)5CC[C@](C)4[C@@](C)3CC[C@@]12[H])=O
-
Synonyms
Betunolic acid; Liquidambaric acid; (+)-Betulonic acid
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (5)
-
Journal Impact Factor
-
Most Recent
-
Pharmacol Res
2024 May 9:204:107208. PMID: 38729587 -
-
Life Sci
TRAF2 mediates Wnt-induced β-catenin nuclear translocation by associating with the nuclear pore complex. [Abstract]2025 May 18:123722. PMID: 40393561 -
Vet Microbiol
The Chinese medicine monomer Schisandrin C inhibits PRRSV infection by regulating the OGT-PI3K/AKT/mTOR signaling pathway. [Abstract]2026 May:316:110992. PMID: 41865607 -
Solvent & Solubility
DMSO : 5 mg/mL (11.00 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 0.67 mg/mL (1.47 mM); Clear solution
This protocol yields a clear solution of ≥ 0.67 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (6.7 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (278 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Bastos DZL, et, al. Biotransformation of betulinic and betulonic acids by fungi. Phytochemistry. 2007 Mar;68(6):834-9. [Content Brief]
[2]. Yang SJ, et, al. Synthesis and biological evaluation of betulonic acid derivatives as antitumor agents. Eur J Med Chem. 2015;96:58-65. [Content Brief]
[3]. Sá MS, et, al. Antimalarial activity of betulinic acid and derivatives in vitro against Plasmodium falciparum and in vivo in P. berghei-infected mice. Parasitol Res. 2009 Jul;105(1):275-9. [Content Brief]
[4]. Pavlova NI, et, al. Antiviral activity of betulin, betulinic and betulonic acids against some enveloped and non-enveloped viruses. Fitoterapia. 2003 Jul;74(5):489-92. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.1993 mL | 10.9967 mL | 21.9935 mL | 54.9837 mL |
| 5 mM | 0.4399 mL | 2.1993 mL | 4.3987 mL | 10.9967 mL | |
| 10 mM | 0.2199 mL | 1.0997 mL | 2.1993 mL | 5.4984 mL |